Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,504 | 434 | 94.0% |
| Education | $401.35 | 8 | 4.0% |
| Consulting Fee | $200.00 | 2 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $1,317 | 84 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,262 | 55 | $0 (2024) |
| ViiV Healthcare Company | $1,249 | 103 | $0 (2024) |
| Janssen Biotech, Inc. | $607.85 | 22 | $0 (2020) |
| Amgen Inc. | $571.66 | 15 | $0 (2019) |
| Theravance Biopharma, Inc. | $462.46 | 18 | $0 (2018) |
| Allergan Inc. | $443.31 | 21 | $0 (2019) |
| Insmed, Inc. | $439.81 | 12 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $434.24 | 13 | $0 (2024) |
| Astellas Pharma US Inc | $361.71 | 14 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $442.21 | 25 | Gilead Sciences, Inc. ($147.33) |
| 2023 | $49.97 | 3 | AIMMUNE THERAPEUTICS, INC. ($19.73) |
| 2022 | $35.34 | 2 | ViiV Healthcare Company ($35.34) |
| 2021 | $28.48 | 1 | Janssen Pharmaceuticals, Inc ($28.48) |
| 2020 | $1,074 | 54 | Paratek Pharmaceuticals, Inc. ($266.42) |
| 2019 | $3,513 | 128 | ViiV Healthcare Company ($405.48) |
| 2018 | $3,032 | 136 | Merck Sharp & Dohme Corporation ($406.86) |
| 2017 | $1,931 | 95 | Gilead Sciences Inc ($340.10) |
All Payment Transactions
444 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.79 | General |
| 12/17/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/11/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $3.86 | General |
| 11/05/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $31.11 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.91 | General |
| 10/16/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: ANTIBIOTIC | ||||||
| 10/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.50 | General |
| 10/01/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/24/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.79 | General |
| 09/04/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $3.78 | General |
| Category: HIV | ||||||
| 09/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.77 | General |
| 08/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.14 | General |
| 07/15/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $113.40 | General |
| Category: HIV | ||||||
| 07/11/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: HIV | ||||||
| 06/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $3.76 | General |
| 05/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.45 | General |
| 04/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.40 | General |
| 03/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.67 | General |
| 03/08/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $3.11 | General |
| Category: HIV | ||||||
| 02/14/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $3.58 | General |
| Category: HIV | ||||||
| 01/08/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $4.46 | General |
| Category: HIV | ||||||
| 01/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.29 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 2,211 | 3,487 | $773,939 | $301,916 |
| 2022 | 12 | 2,301 | 3,847 | $1.0M | $367,890 |
| 2021 | 15 | 1,802 | 3,473 | $600,976 | $336,832 |
| 2020 | 15 | 1,917 | 3,714 | $605,100 | $348,744 |
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 681 | 787 | $247,070 | $110,222 | 44.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 389 | 966 | $257,510 | $94,102 | 36.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 420 | 948 | $162,450 | $61,146 | 37.6% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 124 | 131 | $20,960 | $9,340 | 44.6% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 78 | 87 | $14,550 | $5,941 | 40.8% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 125 | 131 | $23,185 | $5,807 | 25.0% |
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 121 | 130 | $17,124 | $4,119 | 24.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 27 | $7,050 | $3,786 | 53.7% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 82 | 85 | $13,485 | $3,445 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 16 | $3,400 | $1,665 | 49.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 20 | 30 | $1,980 | $1,225 | 61.9% |
| 71045 | X-ray of chest, 1 view | Facility | 2023 | 100 | 115 | $4,025 | $826.89 | 20.5% |
| 71046 | X-ray of chest, 2 views | Facility | 2023 | 33 | 34 | $1,150 | $291.38 | 25.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 800 | 933 | $284,565 | $152,871 | 53.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 532 | 1,757 | $535,885 | $148,429 | 27.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 254 | 380 | $79,800 | $22,423 | 28.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2022 | 144 | 158 | $25,280 | $11,562 | 45.7% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2022 | 122 | 139 | $17,375 | $9,703 | 55.8% |
| 71260 | Ct scan of chest with contrast | Facility | 2022 | 128 | 133 | $24,605 | $6,039 | 24.5% |
| 71250 | Ct scan of chest without contrast | Facility | 2022 | 117 | 128 | $21,120 | $5,421 | 25.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 32 | $9,560 | $4,455 | 46.6% |
| 70450 | Ct scan head or brain without contrast | Facility | 2022 | 107 | 110 | $15,180 | $3,640 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 19 | $4,300 | $1,894 | 44.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 15 | $2,290 | $1,072 | 46.8% |
| 71046 | X-ray of chest, 2 views | Facility | 2022 | 42 | 43 | $1,505 | $379.45 | 25.2% |
About Dr. Bartholomew Bono, MD
Dr. Bartholomew Bono, MD is a Infectious Disease healthcare provider based in Bryn Mawr, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902865603.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bartholomew Bono, MD has received a total of $10,106 in payments from pharmaceutical and medical device companies, with $442.21 received in 2024. These payments were reported across 444 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($9,504).
As a Medicare-enrolled provider, Bono has provided services to 8,231 Medicare beneficiaries, totaling 14,521 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Bryn Mawr, PA
- Active Since 03/21/2006
- Last Updated 04/05/2017
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1902865603
Products in Payments
- PREZCOBIX (Drug) $717.33
- DIFICID (Drug) $649.99
- DOVATO (Drug) $537.32
- VIBATIV (Drug) $462.46
- JULUCA (Drug) $435.95
- NUZYRA (Drug) $434.24
- Aimovig (Biological) $319.79
- ISENTRESS (Drug) $306.29
- Arikayce (Drug) $294.07
- Vascepa (Drug) $270.52
- DALVANCE (Drug) $268.98
- TRIUMEQ (Drug) $261.76
- ZERBAXA (Drug) $217.37
- AVYCAZ (Drug) $160.61
- AMPLATZER Occluders (Device) $134.85
- Cresemba (Drug) $133.66
- Vabomere (Drug) $128.23
- Baxdela (Drug) $127.16
- FARXIGA (Drug) $125.00
- Prolia (Biological) $124.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Bryn Mawr
Dr. Matthew Levison, Md, MD
Infectious Disease — Payments: $52,425
Dr. Hans Liu, M.d, M.D
Infectious Disease — Payments: $43,892
Dr. Peter Spitzer, M.d, M.D
Infectious Disease — Payments: $40,433
Luciano Kapelusznik, Md, MD
Infectious Disease — Payments: $30,561
Adrian Estepa, Md, MD
Infectious Disease — Payments: $983.18
Dr. Young Kim, M.d, M.D
Infectious Disease — Payments: $428.27